Victory Capital Management
BTAI icon

Victory Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Victory Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-473
Closed -$326K – 2755
2021
Q1 		$326K Sell
473
-42,339
-99% -$34.1M ﹤0.01% 2368
2020
Q4 		$31.6M Buy
42,812
+5,669
+15% +$4.42M 0.04% 691
2020
Q3 		$25.8M Buy
37,143
+36,750
+9,351% +$27.6M 0.03% 684
2020
Q2 		$333K Buy
393
+159
+68% +$104K ﹤0.01% 2135
2020
Q1 		$84K Buy
+234
New +$84.1K ﹤0.01% 2592
2019
Q4 		– Sell
-51
Closed -$6K – 2723
2019
Q3 		$6K Buy
+51
New +$8.04K ﹤0.01% 3404

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Victory Capital Management's BTAI Position: Q2 2021 in Review

Victory Capital Management sold out of BioXcel Therapeutics (BTAI) in Q2 2021, closing a stake of 473 shares — an estimated $326K sold.

Victory Capital Management first reported a position in BTAI in Q3 2019 and held it in 6 quarters. The position peaked at $31.6M in Q4 2020. 108 funds tracked by Wall St. Rank hold BTAI as of Q2 2021.

  • Victory Capital Management reported no remaining BioXcel Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Victory Capital Management sold 473 BioXcel Therapeutics shares in Q2 2021, an estimated $326K.
  • Victory Capital Management first reported a position in BioXcel Therapeutics in Q3 2019 and held it in 6 quarters.
  • Victory Capital Management's BioXcel Therapeutics position peaked at $31.6M in Q4 2020.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2021.

Based on Victory Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.